Literature DB >> 14711602

Psychological factors in the irritable bowel syndrome.

M Solmaz1, I Kavuk, K Sayar.   

Abstract

OBJECTIVE: The role of psychological factors in the irritable bowel syndrome (IBS) is a matter of debate. The prevalence of psychiatric disorders is high in IBS patients. Positive response to antidepressant therapy and presence of family history of depression in IBS patients have led speculations whether this syndrome might be regarded as an affective spectrum disorder. In this study we tried to examine the possible association of IBS with affective spectrum disorders.
METHOD: Forty IBS patients from gastroenterology outpatient clinics of a university hospital and state hospital, 32 controls with inflammatory bowel disease and 34 healthy hospital workers were included in the study. Psychiatric interviews were done using SCID-NP (Structured Clinical Interview for DSM-Non-patients) and psychological factors were assessed by the SCL-90-R (Symptom Checklist-90-Revised), the Beck Depression Inventory, the Beck Anxiety Scale and the Hamilton Rating Scale for Depression. Family histories were obtained by FH-RDC (Family History Research Diagnostic Criteria). All groups were matched for sociodemographic variables.
RESULTS: The prevalence of psychiatric disorders and mood disorders was higher in the IBS group than the control groups. Also IBS group rated higher on anxiety and depression scales than the other groups, where the differences were statistically significant. Presence of positive family history for mood disorders was higher in the IBS group.
CONCLUSION: These results support the hypothesis that IBS might be linked to affective spectrum disorder. Psychiatric assessment and therapy might be useful in the course of irritable bowel syndrome.

Entities:  

Mesh:

Year:  2003        PMID: 14711602

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  20 in total

1.  A cross-sectional study of the association between overnight call and irritable bowel syndrome in medical students.

Authors:  Malcolm Wells; Lee Roth; Morgan McWilliam; Kim Thompson; Nilesh Chande
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

Review 2.  Current and emerging pharmacotherapeutic options for irritable bowel syndrome.

Authors:  Jose L Barboza; Nicholas J Talley; Baharak Moshiree
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 3.  Irritable bowel syndrome: a clinical review.

Authors:  Rosa L S Soares
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  Effect of electro-acupuncture at different acupoints on neuropeptide and somatostatin in rat brain with irritable bowel syndrome.

Authors:  Wen-Lian Zhu; Ying Li; Hui-Fang Wei; Xiao-Xuan Ren; Jie Sun; Lu-Fen Zhang; Jiang Zhu
Journal:  Chin J Integr Med       Date:  2012-03-30       Impact factor: 1.978

5.  GERD symptoms in the general population: prevalence and severity versus care-seeking patients.

Authors:  Erica Cohen; Roger Bolus; Dinesh Khanna; Ron D Hays; Lin Chang; Gil Y Melmed; Puja Khanna; Brennan Spiegel
Journal:  Dig Dis Sci       Date:  2014-05-09       Impact factor: 3.199

6.  Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women.

Authors:  Arnstein Mykletun; Felice Jacka; Lana Williams; Julie Pasco; Margaret Henry; Geoffrey C Nicholson; Mark A Kotowicz; Michael Berk
Journal:  BMC Gastroenterol       Date:  2010-08-05       Impact factor: 3.067

Review 7.  CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome.

Authors:  Y Taché; V Martinez; L Wang; M Million
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

8.  Irritable bowel syndrome and dyspepsia among women veterans: prevalence and association with psychological distress.

Authors:  L S Savas; D L White; M Wieman; K Daci; S Fitzgerald; S Laday Smith; G Tan; D P Graham; J A Cully; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2008-09-09       Impact factor: 8.171

9.  Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?

Authors:  Y Taché
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 10.  Use of rifaximin in gastrointestinal and liver diseases.

Authors:  Rani H Shayto; Rachel Abou Mrad; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.